Reyvow ® (lasmiditan) tablets CV

50 mg, 100 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

VIDEO: Reyvow® (lasmiditan): CENTURION Study Clinical Trial Design

CENTURION was a phase 3 double-blind, placebo-controlled study that evaluated the first attack efficacy, consistency of response, and safety of Reyvow (lasmiditan) in the acute treatment of 4 migraine attacks with or without aura.

Date of Last Review: September 22, 2021

Document Number: VV-MED-113985

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical